# An Extension Study for Patients Previously Treated With ARQ 501

> **NCT00622063** · PHASE1,PHASE2 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 1 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** ARQ 501

## Key facts

- **NCT ID:** NCT00622063
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622063, "An Extension Study for Patients Previously Treated With ARQ 501". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00622063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*